Analyst Price Targets — INMB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 22, 2024 7:35 am | George Farmer | Scotiabank | $22.00 | $6.85 | TheFly | Scotiabank starts INmune with Outperform on Alzheimer's potential |
Latest News for INMB
BOCA RATON, Fla. , April 16, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage biotechnology company focused on developing therapies that harness the patient's innate immune system, today announces new preclinical data for INB03 (XPro1595 for oncology).
Shares of INmune Bio, Inc. (NASDAQ: INMB - Get Free Report) have been assigned a consensus rating of "Hold" from the six brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 and provides a business update.
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INMB.
U.S. House Trading
No House trades found for INMB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.